Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug aims to halt deadly Heart-Stiffening disease

NCT ID NCT03997383

Ongoing Disease control Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether the drug patisiran can help people with ATTR amyloidosis, a condition where abnormal proteins build up and stiffen the heart muscle. It involves 360 participants who have heart failure symptoms from this disease. Researchers will measure if the drug improves how far people can walk in 6 minutes, reduces hospital visits, and improves their quality of life over 12 months.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Clinical Trial Site

    Los Angeles, California, 90048, United States

  • Clinical Trial Site

    Chicago, Illinois, 60637, United States

  • Clinical Trial Site

    Skokie, Illinois, 60076, United States

  • Clinical Trial Site

    Iowa City, Iowa, 52242, United States

  • Clinical Trial Site

    Kansas City, Kansas, 66160, United States

  • Clinical Trial Site

    Baltimore, Maryland, 21224, United States

  • Clinical Trial Site

    Boston, Massachusetts, 02118, United States

  • Clinical Trial Site

    Burlington, Massachusetts, 10805, United States

  • Clinical Trial Site

    Rochester, Minnesota, 55905, United States

  • Clinical Trial Site

    St Louis, Missouri, 63110, United States

  • Clinical Trial Site

    New York, New York, 10029, United States

  • Clinical Trial Site

    New York, New York, 10032, United States

  • Clinical Trial Site

    Cleveland, Ohio, 44195, United States

  • Clinical Trial Site

    Philadelphia, Pennsylvania, 19104, United States

  • Clinical Trial Site

    Philadelphia, Pennsylvania, 19140, United States

  • Clinical Trial Site

    Pittsburgh, Pennsylvania, 15212, United States

  • Clinical Trial Site

    Nashville, Tennessee, 37232, United States

  • Clinical Trial Site

    Dallas, Texas, 75246, United States

  • Clinical Trial Site

    Norfolk, Virginia, 23507, United States

  • Clinical Trial Site

    Buenos Aires, Buenos Aires, C1039AAO, Argentina

  • Clinical Trial Site

    San Juan Bautista, Buenos Aires, B1888AAE, Argentina

  • Clinical Trial Site

    Córdoba, Córdoba Province, X5000KEH, Argentina

  • Clinical Trial Site

    Rosario, Santa Fe Province, S2000DSR, Argentina

  • Clinical Trial Site

    Rosario, Santa Fe Province, S2000DTC, Argentina

  • Clinical Trial Site

    Rosario, Santa Fe Province, S2000PBJ, Argentina

  • Clinical Trial Site

    Santa Fe, Santa Fe Province, S3000FWO, Argentina

  • Clinical Trial Site

    Buenos Aires, C1428AQK, Argentina

  • Clinical Trial Site

    Westmead, New South Wales, 2145, Australia

  • Clinical Trial Site

    Woolloongabba, Queensland, 4021, Australia

  • Clinical Trial Site

    Box Hill, Victoria, 3128, Australia

  • Clinical Trial Site

    Liège, LIE, 4000, Belgium

  • Clinical Trial Site

    Hasselt, LIM, 3500, Belgium

  • Clinical Trial Site

    Aalst, OVL, 9300, Belgium

  • Clinical Trial Site

    Roeselare, WVL, 8800, Belgium

  • Clinical Trial Site

    Porto Alegre, Rio Grande do Sul, 90035-030, Brazil

  • Clinical Trial Site

    Ribeirão Preto, São Paulo, 14026-900, Brazil

  • Clinical Trial Site

    Ribeirão Preto, São Paulo, 14048-900, Brazil

  • Clinical Trial Site

    São Paulo, São Paulo, 05403-000, Brazil

  • Clinical Trial Site

    Rio de Janeiro, 22280-000, Brazil

  • Clinical Trial Site

    São Paulo, 04012-909, Brazil

  • Clinical Trial Site

    Sofia, Sofia-Grad, 1784, Bulgaria

  • Clinical Trial Site

    Sofia, 1680, Bulgaria

  • Clinical Trial Site

    Stara Zagora, 6000, Bulgaria

  • Clinical Trial Site

    Santiago, 7500587, Chile

  • Clinical Trial Site

    Prague, Praha, Hlavní Mesto, 120 00, Czechia

  • Clinical Trial Site

    Brno, 656 91, Czechia

  • Clinical Trial Site

    Prague, 128 08, Czechia

  • Clinical Trial Site

    Prague, 140 21, Czechia

  • Clinical Trial Site

    Aarhus N, Aarhus, 8200, Denmark

  • Clinical Trial Site

    Copenhagen, 2100, Denmark

  • Clinical Trial Site

    Odense C, 5000, Denmark

  • Clinical Trial Site

    Clichy, Paris, 92110, France

  • Clinical Trial Site

    Créteil, Val-de-Marne, 94010, France

  • Clinical Trial Site

    Rennes, 35033, France

  • Clinical Trial Site

    Toulouse, 31059, France

  • Clinical Trial Site

    Lai Chi Kok, 999077, Hong Kong

  • Clinical Trial Site

    Bologna, Emilia-Romagna, 40138, Italy

  • Clinical Trial Site

    Messina, Sicily, 98125, Italy

  • Clinical Trial Site

    Florence, 50134, Italy

  • Clinical Trial Site

    Pavia, 27100, Italy

  • Clinical Trial Site

    Nagoya, Aichi-ken, 466-8560, Japan

  • Clinical Trial Site

    Kurume, Fukuoka, 830-0011, Japan

  • Clinical Trial Site

    Matsumoto, Nagano, 390-8621, Japan

  • Clinical Trial Site

    Suita, Osaka, 565-8565, Japan

  • Clinical Trial Site

    Bunkyo-ku, Tokyo, 113-8655, Japan

  • Clinical Trial Site

    Fukuoka, 812-8582, Japan

  • Clinical Trial Site

    Kumamoto, 860-8556, Japan

  • Clinical Trial Site

    Mexico City, 14080, Mexico

  • Clinical Trial Site

    Groningen, 9713 GZ, Netherlands

  • Clinical Trial Site

    Maastricht, 6229 HX, Netherlands

  • Clinical Trial Site

    Christchurch, 8011, New Zealand

  • Clinical Trial Site

    Hamilton, 3204, New Zealand

  • Clinical Trial Site

    Lódz, Lódzkie, 90-127, Poland

  • Clinical Trial Site

    Warsaw, Masovian Voivodeship, 01-192, Poland

  • Clinical Trial Site

    Warsaw, Masovian Voivodeship, 04-628, Poland

  • Clinical Trial Site

    Gdansk, Pomeranian Voivodeship, 80-382, Poland

  • Clinical Trial Site

    Katowice, Silesian Voivodeship, 40-635, Poland

  • Clinical Trial Site

    Porto, 4099-001, Portugal

  • Clinical Trial Site

    Senhora da Hora, 4464-513, Portugal

  • Clinical Trial Site

    Viseu, 3504-509, Portugal

  • Clinical Trial Site

    Seoul, 3080, South Korea

  • Clinical Trial Site

    Stockholm, 17164, Sweden

  • Clinical Trial Site

    Taipei, 11217, Taiwan

  • Clinical Trial Site

    Bellshill, Lanarkshire, ML4 3NJ, United Kingdom

  • Clinical Trial Site

    London, London, City of, SE1 1YR, United Kingdom

  • Clinical Trial Site

    Hexham, Northumberland, NE46 1QJ, United Kingdom

  • Clinical Trial Site

    Birmingham, West Midlands, B15 2SQ, United Kingdom

  • Clinical Trial Site

    Cardiff, CF15 9SS, United Kingdom

  • Clinical Trial Site

    London, NW3 2PF, United Kingdom

  • Clinical Trial Site

    Manchester, M15 6SE, United Kingdom

Conditions

Explore the condition pages connected to this study.

TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY